SCHEMBL938726

SCHEMBL938726

Cc1ccc2c(N3CCC(N)CC3)nc(-c3ccccc3O)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMAD3 P84022 1/20 0.56
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
CHEK2 O96017 3/20 0.54
ALDH1A1 P00352 6/20 0.49
TSHR P16473 5/20 0.49
MAPT P10636 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
KDM4E B2RXH2 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
HIF1A Q16665 1/20 0.46
HRH4 Q9H3N8 1/20 0.45
CYP1A2 P05177 3/20 0.43
CYP3A4 P08684 3/20 0.43
HSD17B10 Q99714 3/20 0.43
CYP2D6 P10635 2/20 0.43
USP2 O75604 3/20 0.42
CLK4 Q9HAZ1 2/20 0.42
MAPK1 P28482 2/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4014391 0.99 SMAD3 (0.55) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL183511 0.94 CHEK2 (0.58) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL183512 0.94 CHEK2 (0.58) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL184238 0.94 CHEK2 (0.58) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL1084790 0.91 SMAD3 (0.58) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL13768748 0.89 KMT2A (0.52) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL1623718 0.88 SMAD3 (0.55) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL1084462 0.88 TSHR (0.58) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL1623958 0.88 SMAD3 (0.55) SMAD3KMT2AMEN1CHEK2ALDH1A1
SCHEMBL1623723 0.88 SMAD3 (0.55) SMAD3KMT2AMEN1CHEK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343980-B2 Quinazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
US-8343980-B2 Quinazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
US-8343980-B2 Quinazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
CN-101068794-B Quinazolines useful as modulators of ion channels VERTEX PHARMA 2012-12-19 CN disclosed
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-8153642-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-8153642-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-8153642-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 EP disclosed
US-20060217377-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-09-28 US disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
CN-1784391-A Quinazolines useful as modulators of ion channels VERTEX PHARMA (US) 2006-06-07 CN disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 WO disclosed
EP-1608632-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2005-12-28 EP disclosed
US-20040248890-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2004-12-09 US disclosed
WO-2004078733-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-09-16 WO disclosed
WO-2004078733-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 SMAD3 4194/4885KMT2A 2404/4885MEN1 2548/4885
US-20040248890-A1 Quinazolines useful as modulators of ion channels KCNN3, KCNN2, CACNA1I SMAD3 3643/4885KMT2A 2608/4885MEN1 2516/4885
US-20060217377-A1 Quinazolines useful as modulators of ion channels KCNN3, KCNN2, CACNA1I SMAD3 3643/4885KMT2A 2608/4885MEN1 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.